Loading...
01/10 16:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
Revenue for the third quarter $0.6 million, a 32% increase year-over-year. The increase is attributed to the early stage of commercialization, though revenues remain unpredictable.
Operating expenses for the quarter Down 10% year-over-year and down 18% for the first three quarters. The decrease is primarily due to lower personnel costs and reduced research and development expenses.
Net cash used in operating activities $3.6 million for the quarter, a 33% reduction year-over-year. This improvement is due to strong cost management.
Net loss for the quarter Down 8% year-over-year and down 20% for the first three quarters. The reduction is attributed to cost management and lower operating expenses.
Receipts during the third quarter $1.2 million from a registered direct offering, including participation by some directors.
Subsequent to quarter end Net proceeds of approximately $6.1 million from a confidentially marketed public offering, including partial exercise of the underwriters' overallotment option.
Nu.Q platform commercialization: Signed agreements with Werfen and Hologic for APS and co-marketing Nu.Q Discover service respectively. Werfen will validate Nu.Q NETs assay for APS management, a market worth $85 million annually. Hologic will expand Nu.Q Discover services for epigenetic profiling.
Capture-Seq technology: Developed a new liquid biopsy method targeting cancer-derived DNA, achieving 100% sensitivity and specificity in initial tests. This method isolates transcription factor-bound DNA, representing a new class of cancer biomarkers.
Nu.Q Vet cancer test: Progress in automating centralized lab platforms with Fujifilm Vet Systems to expand canine cancer screening. Targeting inclusion in annual pet wellness panels for 2026.
APS market: APS diagnosis and monitoring represent a $85 million annual market. Nu.Q NETs test could improve diagnostics and monitoring.
Cancer and sepsis diagnostics: Combined total addressable market of $25 billion annually, with potential for significant revenue growth through licensing agreements.
Revenue growth: Revenue grew 32% year-over-year to $0.6 million in Q3 2025.
Cost management: Operating expenses decreased by 10% year-over-year, and cash used in operations reduced by 33%.
Licensing agreements: Focused on securing licensing agreements in human diagnostics, mirroring veterinary market strategy.
Global expansion: Expanding Nu.Q Vet cancer test globally through partnerships with Antech, Fujifilm Vet Systems, and IDEXX.
Market Conditions: Revenue for the third quarter grew 32% over the same quarter last year, but revenues remain fairly lumpy and difficult to predict from one quarter to the next. This unpredictability poses a challenge for financial planning and stability.
Strategic Execution Risks: The company is heavily reliant on executing several significant licensing agreements in the human diagnostics space and securing milestone payments in the veterinary space to achieve cash neutrality. Failure to close these deals could impact financial sustainability.
Regulatory Hurdles: The company is working on validating and verifying its tests in various markets, which may face regulatory challenges and delays, particularly in the human diagnostics space.
Economic Uncertainties: The company has made progress in cost reductions, but achieving cash neutrality is contingent on external factors like licensing agreements and milestone payments, which are subject to market and economic conditions.
Supply Chain and Operational Risks: The company is focused on centralized lab automation to handle larger test volumes. Any delays or issues in automation implementation could hinder growth and operational efficiency.
Competitive Pressures: The company is in discussions with around 10 leading diagnostic and liquid biopsy companies. The competitive landscape could impact the company's ability to secure favorable licensing agreements and market share.
Revenue Guidance: The company will not be providing revenue guidance at this point in time due to the early stage of commercialization and the unpredictable nature of revenues.
Licensing Agreements: The company is focused on executing several significant licensing agreements in the human diagnostics space and securing milestone payments in the veterinary space to achieve cash neutrality.
Nu.Q Vet Cancer Test: The company aims to expand the global reach of the Nu.Q Vet cancer test, focusing on centralized lab automation to accelerate revenue growth. The goal is to include the test in annual pet wellness panels by 2026, which would significantly increase sales volumes.
Nu.Q NETs Commercialization: The company plans to leverage its CE Mark approval in the EU for NETosis-related diseases and anticipates presenting and publishing results regarding the clinical utility of the Nu.Q NETs H3.1 assay across a range of diseases in the coming months and quarters.
Capture-Seq Technology: The company has developed a new liquid biopsy method, Capture-Seq, which isolates cancer-derived DNA with high specificity and sensitivity. This technology is expected to be a game changer in the liquid biopsy field and is currently in active discussions with third parties for potential licensing.
Nu.Q Discover Service: The company has partnered with Hologic to co-market the Nu.Q Discover service, which provides assays for epigenetic profiling. This partnership is expected to accelerate the expansion of Nu.Q services to a wider customer base and drive revenue growth.
Cancer and Sepsis Diagnostics: The company is targeting the cancer and sepsis diagnostics market, which represents a combined total addressable market of approximately $25 billion annually.
The selected topic was not discussed during the call.
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
The earnings call presents mixed signals. While there are positive aspects like revenue growth, cost management, and milestone payments, the absence of revenue guidance and declining cash position raise concerns. The Q&A section reveals uncertainty in revenue predictability and challenges in maintaining cost levels. Overall, the lack of specific guidance and potential financial risks balance out the positives, suggesting a neutral sentiment towards the stock price movement.
The earnings call presents mixed signals: strong revenue growth and reduced expenses are positive, but lack of 2025 guidance and regulatory uncertainties are concerns. The Q&A reveals cautious optimism about new projects and milestone payments, but management's unclear responses on some topics raise doubts. Overall, the absence of clear guidance and competitive pressures balance out the positive financial metrics, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
